Eiropas Savienība - latviešu - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - visi pārējie terapeitiskie produkti - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ombitasvir, paritaprevir, ritonavir - c hepatīts, hronisks - pretvīrusu līdzekļi sistēmiskai lietošanai - viekirax ir minēta kopā ar citām zālēm, ārstēšanai hronisku c hepatītu (chc) pieaugušajiem. hepatīta c vīrusa (hcv) genotipa specifiska aktivitāte.

Latvija - latviešu - Zāļu valsts aģentūra

laboratorios liconsa, s.a., spain - valsartāns - apvalkotā tablete - 80 mg

Latvija - latviešu - Zāļu valsts aģentūra

laboratorios liconsa, s.a., spain - valsartāns - apvalkotā tablete - 160 mg

Latvija - latviešu - Zāļu valsts aģentūra

merck serono, sia, latvia - bisoprolola fumarāts - apvalkotā tablete - 2,5 mg

Latvija - latviešu - Zāļu valsts aģentūra

merck serono, sia, latvia - bisoprolola fumarāts - apvalkotā tablete - 5 mg

Latvija - latviešu - Zāļu valsts aģentūra

baxter holding b.v., netherlands - natrii hydrogenocarbonas, natrii chloridum, kalcija chloridum dihydricum, magnija chloridum hexahydricum, skābes lacticum - Šķīdums hemodialīzei/hemofiltrācijai

Latvija - latviešu - Zāļu valsts aģentūra

mcneil healthcare (ireland) limited, ireland - ksilometazolīna hidrohlorīds - deguna aerosols, šķīdums - 0,5 mg/ml

Latvija - latviešu - Zāļu valsts aģentūra

mcneil healthcare (ireland) limited, ireland - ksilometazolīna hidrohlorīds - deguna aerosols, šķīdums - 1 mg/ml